Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 6, 2011, Pages

  Elsheikh, Ayman ^a,b   Castrejon, Luis ^a   Lavergne, Sidonie N ^a,c   Whitaker, Paul ^d   Monshi, Manal ^a,e   Callan, Hayley ^a   El Ghaiesh, Sabah ^a,b   Farrell, John ^a   Pichler, Werner J ^f   Peckham, Daniel ^d   Park, B Kevin ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b TANTA UNIVERSITY   (Egypt)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e KING FAHAD MEDICAL CITY   (Saudi Arabia)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

cystic fibrosis; drug hypersensitivity; drug metabolism; Human; T cells

Indexed keywords

1 AMINOBENZOTRIAZOLE; ANTIGEN; ENZYME INHIBITOR; GAMMA INTERFERON; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; SULFAMETHOXAZOLE; THIAMAZOLE;

ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL KILLING; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHRODERMA; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALAISE; METABOLITE; PHENOTYPE; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TARGET CELL; TREATMENT RESPONSE;

EID: 79957834898     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.12.1119     Document Type: Article

References (45)

1. Lavergne SN, Whitaker P, Peckham D, Conway S, Park BK, Naisbitt DJ. Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. Chem Res Toxicol 2010;23:1009-11.
2. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991;13(suppl 7):S608-11.
3. Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994;106:1124-8. (Pubitemid 24309550)
4. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res 2007;56:221-7.
5. Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 2009;123:986-94, quiz 5-6.
6. Ntimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M, et al. Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev 2009;30:153-77.
7. Castrejon JL, Berry N, El-Ghaiesh S, Gerber B, Pichler WJ, Park BK, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 2010;125:411-8, e4.
8. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4(+), CD8(+), and CD4(+)CD8(+) T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-81. (Pubitemid 46527813)
9. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+T cells from allergic individuals. J Immunol 2000;164:6647-54. (Pubitemid 30408852)
10. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15. (Pubitemid 39469167)
11. Rozieres A, Hennino A, Rodet K, Gutowski MC, Gunera-Saad N, Berard F, et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009;64:534-42.
12. Elsheikh A, Lavergne SN, Castrejon JL, Farrell J, Wang H, Sathish J, et al. Drug antigenicity, immunogenicity and co-stimulatory signalling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010;185:6448-60.
13. Lavergne SN, Wang H, Callan HE, Park BK, Naisbitt DJ. "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther 2009;331:372-81.
14. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175-81. (Pubitemid 27085418)
15. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-41. (Pubitemid 43964854)
16. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001;133:295-305. (Pubitemid 32507049)
17. Burkhart C, von Greyerz S, Depta JP, Naisbitt DJ, Britschgi M, Park KB, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001;132:623-30. (Pubitemid 32165177)
18. Sanderson JP, Naisbitt DJ, Farrell J, Ashby CA, Tucker MJ, Rieder MJ, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007;178:5533-42. (Pubitemid 46674348)
19. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591-8. (Pubitemid 28492227)
20. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
21. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79. (Pubitemid 351214284)
22. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28:822-32. (Pubitemid 351784513)
23. Alfirevic A, Vilar FJ, Alsbou M, Jawaid A, Thomson W, Ollier WE, et al. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. Pharmacogenomics 2009;10:531-40.
24. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
25. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003;55:158-65. (Pubitemid 36237861)
26. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000;10:705-13.
27. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001;1:311-6.
28. Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1995;96:65-97.
29. Wetmore DR, Joseloff E, Pilewski J, Lee DP, Lawton KA, Mitchell MW, et al. Metabolomic profiling revealed biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. J Biol Chem 2010;285:30516-22.
30. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992;51:522-6.
31. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990;18:784-7. (Pubitemid 20348877)
32. Callan HE, Jenkins RE, Maggs JL, Lavergne SN, Clarke SE, Naisbitt DJ, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009;22:937-48.
33. Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002;62:628-37. (Pubitemid 36329381)
34. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126:1393-407. (Pubitemid 29142071)
35. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: implications for idiosyncratic toxicity. Drug Metab Dispos 1991;19:900-6.
36. Summan M, Cribb AE. Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem Biol Interact 2002;142:155-73. (Pubitemid 35232557)
37. Manchanda T, Hess D, Dale L, Ferguson SG, Rieder MJ. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 2002;62:1011-26. (Pubitemid 35222492)
38. Castrejon JL, Lavergne SN, El-Sheikh A, Farrell J, Maggs JL, Sabbani S, et al. Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives. Chem Res Toxicol 2010;23:184-92.
39. Farrell J, Naisbitt DJ, Drummond NS, Depta JP, Vilar FJ, Pirmohamed M, et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003;306:229-37. (Pubitemid 36734377)
40. Roychowdhury S, Vyas PM, Svensson CK. Formation and uptake of arylhydroxylamine-haptenated proteins in human dendritic cells. Drug Metab Dispos 2007;35:676-81. (Pubitemid 46513272)
41. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005;314:43-52. (Pubitemid 41058239)
42. Rozieres A, Vocanson M, Said BB, Nosbaum A, Nicolas JF. Role of T cells in non-immediate allergic drug reactions. Curr Opin Allergy Clin Immunol 2009;9:305-10.
43. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229-38. (Pubitemid 34615386)
44. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-5. (Pubitemid 39391928)
45. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003;63:732-41. (Pubitemid 36297347)